2023
Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysis
2017
Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice
Rosenberg SA, Baschnagel AM, Bagley SJ, Housri N. Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. Current Oncology Reports 2017, 19: 5. PMID: 28168606, DOI: 10.1007/s11912-017-0563-z.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentLung cancer treatmentNational clinical trialEvidence-based treatmentsEvidence-based medicineTranslating EvidenceCommunity oncologistsBody radiotherapyLung cancerClinical trialsPreclinical discoveryClinical practiceCommunity settingsCancer treatmentOncologistsCommunity practiceTreatmentMedicineImmunotherapyNSCLCInternet-based resourcesRadiotherapyCancer